Helix Biopharma (HBPCF) Short Interest Ratio & Short Volume

The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. HBPCF shares currently have a short interest ratio of 0.3. Learn More on Helix Biopharma's short interest ratio.

Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 0.00% of Helix Biopharma's floating shares are currently sold short.

0.00% of Helix Biopharma's shares are currently sold short. Here is how the short interest of companies in the industry of "med - biomed/gene" compare to Helix Biopharma: Kyverna Therapeutics, Inc. (11.46%), Ovid Therapeutics (6.13%), Contineum Therapeutics, Inc. (4.32%), Autolus Therapeutics PLC Sponsored ADR (6.47%), Immix Biopharma, Inc. (10.64%), Sutro Biopharma, Inc. (4.82%), C4 Therapeutics, Inc. (20.74%), Coeptis Therapeutics Holdings, Inc. (1.61%), Adlai Nortye Ltd. Sponsored ADR (8.02%), Emergent Biosolutions Inc. (20.12%),

As of the most recent reporting period, the following stocks had the largest short interest positions: SPDR S&P 500 ETF Trust ($87.12 billion), Invesco QQQ ($35.64 billion), iShares Russell 2000 ETF ($24.70 billion), Salesforce Inc. ($14.51 billion), SPDR S&P Biotech ETF ($10.91 billion), iShares iBoxx $ High Yield Corporate Bond ETF ($9.55 billion), iShares iBoxx $ Investment Grade Corporate Bond ETF ($9.16 billion), iShares 20+ Year Treasury Bond ETF ($8.62 billion), Lumentum Holdings Inc. ($8.06 billion), and Western Digital Corporation ($7.21 billion). View all of the most shorted stocks.

Short selling HBPCF is an investing strategy that aims to generate trading profit from Helix Biopharma as its price is falling. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit.

A short squeeze for Helix Biopharma occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of HBPCF, which in turn drives the price of the stock up even further.

Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including HBPCF, twice per month. The most recent reporting period available is March, 31 2026.